Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.
- March 31, 2023
Hospital laboratories face ever-increasing pressure for cost control as well as demands from clinicians for faster diagnostic results. Until now, laboratories have had to rely on methods that were introduced almost 100 years ago to determine the presence and identification of bacterial and fungal infections.
New direct-from-whole blood T2Direct Diagnostics™ have been proven to complement traditional blood culture methods by identifying the most common and deadly organisms resistant to empiric therapy. With T2Direct Diagnostics tools, laboratories can now provide species-specific results in 3 to 5 hours instead of 1 to 5 or more days. The benefits include more rapid targeted treatments for patients,* a potential to de-escalate drug use, and length of stay.
Designed with the laboratory in mind, the T2Dx® Instrument fits within the most space-constrained environment. The fully automated, walkaway T2Dx is a clinical multiplex benchtop diagnostic system capable of running tests directly from 3-4 mL of whole blood. The T2Dx is:
For more information on T2Direct Diagnostics, see the latest publications, posters, and white papers. Learn how T2 Biosystems’ T2MR® technology works or read in the Medical Laboratory Observer’s cover story and the Healio Infectious Disease News story.
* Henry Ford Health System demonstrated patients tested with the T2Candida Panel were treated in a median of 5 hours – more than an eightfold improvement compared to blood culture.3 Similarly, Lee Health found the time to initiation of appropriate antifungal therapy was only 6 hours from the time of blood draw in the T2Candida-positive patients.4
‡ T2Direct Diagnostics tools can help de-escalate therapy, leading to pharmacy savings and reduced nephrotoxic side effects on patients. Hospitals, including Lee Health, Huntsville Hospital, and University of Pittsburgh Medical Center have reported antifungal savings that more than covered the full cost of testing at their institutions, with as much as a 2.1 day reduction of micafungin therapy per patient.4,5,6
Contact us to request a demo of the T2Dx Instrument!
1. Mylonakis E, et al. Clinical Infectious Diseases, 2015
2. T2Bacteria Pivotal Clinical Study 2018. Manuscript under review.
3. Wilson NM, et al. Journal of Antimicrobial Stewardship, 2017
4. Patch ME, et al. Journal of Antimicrobial Chemotherapy, 2018
5. Edwards JD. Poster Presentation, ASM Microbe, 2017
6. Shields R, et al. Poster Presentation, IDWeek, 2018
FDA-cleared, direct-from-blood diagnostic tools:
Over 200 studies published in peer-reviewed journals have featured T2MR in a breadth of applications